September 4, 2025
There's also a case for taking partial profits in stronger names rather than waiting for them to buckle
Econs are coming, econs are coming; get ready for the resistance
BREAKING: U.S. private sector hiring rose less than expected in August and significantly cooled from the prior month, according to the ADP. Private payrolls increased by just 54 K in August, well short of the 75 K estimate from economists and down from the revised gain of 106 K jobs added in July. Jobs tied to trade, transportation and utilities saw particular weakness in August, with the group losing 17 K roles on net, according to the ADP. Education and health services followed, recording a decline of 12 K jobs. Those losses were offset in part by a boom in the leisure and hospitality industry, which added 50 K jobs in the month. Wage growth maintained the same pace in August. Those staying in their roles saw their pay rise 4.4% year-over-year, while job changes recorded a 7.1% increase over the same period.
News: Mesoblast (MESO +$0.62 <pre-open> to $13.50) has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck to issue, at its sole discretion, up to US$50 M of unsecured convertible notes.
Pre-open Signals: 3 Positive, 1 Negative and 3 Sell into Strength
Never leave an investor uninformed … I say what others won’t, so you can do what others can’t!
September 2, 2025
A net loss of -$18.23 M or -$0.11 per share, revenue of $317 K <cost of sales = $302 K>, a cash position of $786 K <liabilities -$1.376 M>, with a runway until Q3/25.
What happened and where is the $2 M "Exempt Offering of Securities" Trouble in offering land?
Accumulated deficit to date= $103.2 M
U.S. investors BEWARE, forewarned is forearmed?
September 4, 2025
As the market and employment data randomization of sector’s share pricing
After I wrote this a.m., “Time to reap the share pricing fruit … There's also a case for taking partial profits in stronger names rather than waiting for them to buckle”
News: Sangamo Therapeutics (SGMO -$0.0038 to $0.53) detailed data from the registrational P1/2 STAAR study evaluated isaralgagene civaparvovec, or ST-920, an investigational gene therapy for the treatment of adults with Fabry disease. The ability for patients to discontinue the use of burdensome enzyme replacement therapies further supports the potential of ST-920 as a single-dose, durable treatment option for people living with Fabry disease.
Remember, “The sector is what it is, until it isn’t, even if it doesn’t seem to be, it yet will be.” Never leave an investor uninformed!
September 2, 2025
A net loss of -$18.23 M or -$0.11 per share, revenue of $317 K <cost of sales = $302 K>, a cash position of $786 K <liabilities -$1.376 M>, with a runway until Q3/25. What happened and where is the $2 M "Exempt Offering of Securities" Trouble in offering land? Accumulated deficit to date= $103.2 M U.S. investors BEWARE, forewarned is forearmed?
August 28, 2025
Stay with me … Who is speaking-up for investors? I write this blog/newsletter about – facts in evidence! I will still answer or qualify the sector’s equity’s share pricing mobility; with an emphasis on which company is gaining or losing stride in your portfolio in the short and near-term I also follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”
August 13, 2025
Of 32.29 M shares priced at $2.99 per share With the usual pre-funded warrants <6 M> CMPX traded down -$0.015 or -0.4732% to $3.16 mid-day Expecting gross proceeds from the offering to CMPX to be approximately $120 M
5 hours 20 min ago
RegMed Investors (RMi) Closing Bell: Econs shuffle the sector’s cards
14 hours 24 min ago
RegMed Investors’ (RMi) pre-open: Time to reap the share pricing fruit
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
